Vladimir Makarov,
Chief Scientific Officer,
Swift Biosciences Inc
Vladimir has a track record spanning more than 30 years in cutting edge molecular biology, with broad expertise in physics, molecular biology, genomics, and molecular diagnostics. Vladimir has authored more than 30 issued and pending patents and 60 scientific publications. He has co-founded 2 biotech start-ups, leading to development and commercialization of more than 10 different products in the research tools and diagnostics space. Prior to Swift, Vladimir served as Chief Scientific Officer of Rubicon Genomics, and was the key inventor of Rubicon products. Vladimir was responsible for creating Rubicon’s product vision, research and development, and intellectual property management. Vladimir received his PhD in Physics and Mathematics from St. Petersburg University and has held senior scientist positions at the University of Michigan (Ann Arbor) and the Institute of Molecular Biology (Moscow).
Single Copy qPCR-Based Detection of BRAF and KRAS Mutations
Thursday, 19 April 2012 at 11:15
Add to Calendar ▼2012-04-19 11:15:002012-04-19 12:15:00Europe/LondonSingle Copy qPCR-Based Detection of BRAF and KRAS MutationsSELECTBIOenquiries@selectbiosciences.com
The development of highly sensitive genotyping assays that are suitable for clinical diagnostics opens new opportunities for the detection, assessment, and management of cancer. Anticipated uses for these assays include profiling tissue biopsies, circulating tumor cells (CTCs), and detecting mutations in circulating cell-free nucleic acids. Swift Biosciences™ has developed myT™ Primers which have unique structural and thermodynamic properties that make them highly sensitive to mismatch discrimination. A myT Primer assay for BRAF V600E/K mutations demonstrated single mutant copy sensitivity in a background of 14,000 wild-type genomic DNA copies. This assay also demonstrated high specificity as indicated by a low percentage (< 3%) of amplification events from 14,000 wild-type genomic copies. myT Primer assays are compatible with multiple qPCR instruments and reaction mixes. myT Primer qPCR assays for seven common KRAS mutations demonstrated similar sensitivity and specificity. When compared to a leading commercially available KRAS mutation qPCR test kit, several orders of improved specificity were observed. The extreme selectivity of myT Primer assays will be especially useful for detection of mutations present at ultra-low copy number and for genotyping difficult samples such as needle biopsies, CTCs, and serum, resulting in better detection, evaluation, and monitoring of cancer.
Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonAdvances in qPCRSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2012-04-19 11:15:002012-04-19 12:15:00Europe/LondonSingle Copy qPCR-Based Detection of BRAF and KRAS MutationsSELECTBIOenquiries@selectbiosciences.com
